Your session is about to expire
← Back to Search
A197 Ophthalmic Solution for Dry Eye Syndrome
Study Summary
This trial is assessing the safety and effectiveness of a new eye solution for people with Dry Eye Disease.
- Dry Eye Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there still opportunity to join this research initiative?
"As per the information on clinicaltrials.gov, this particular trial has concluded its recruitment phase and is no longer seeking participants. Initially posted on January 25th 2022, it was last updated November 8th 2022. However, 134 other trials are currently accepting patients for enrolment."
Has the FDA conferred its stamp of approval to A197 Ophthalmic Solution?
"Studied data indicates that A197 Ophthalmic Solution is likely to be safe, so it was assessed a score of 2. This trial has yet to demonstrate any efficacy in clinical trials."
How many healthcare facilities are engaged in this investigation?
"19 sites are currently enrolling for this trial, such as Aramis Site 121 in Garden Grove, Aramis Site 120 in Glendale, and Aramis Site 113 in Birmingham."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger